United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corporation furnished a Form 8-K announcing it issued a press release with earnings for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The company stated this information shall not be deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into Securities Act filings, except as specifically referenced.
United Therapeutics reported stronger results for the quarter ended September 30, 2025. Total revenues were $799.5 million versus $748.9 million a year ago, and net income rose to $338.7 million from $309.1 million. Diluted EPS was $7.16 (up from $6.39).
Growth was led by Tyvaso DPI at $336.2 million, Orenitram at $131.1 million, and Nebulized Tyvaso at $141.8 million. Operating income reached $388.5 million, while nine‑month operating cash flow totaled $1,215.0 million. Cash and cash equivalents were $1,340.1 million and available‑for‑sale securities carried a fair value of $3,019.0 million as of quarter‑end.
The company executed a $1.0 billion accelerated share repurchase program consisting of uncollared and collared tranches, with initial share deliveries completed and final settlements expected in the fourth quarter of 2025 and first quarter of 2026. A new unsecured revolving credit facility of up to $2.5 billion was established in April 2025 and had no outstanding balance at quarter‑end. Shares outstanding were 43,056,599 as of October 22, 2025.
In litigation with Sandoz, a final judgment ordered payment of approximately $61.6 million in damages plus about $9.0 million in prejudgment interest, with appeals pending.
United Therapeutics (UTHR): The President and COO reported option exercises and related share sales on 10/27/2025 under a Rule 10b5-1 plan dated June 3, 2025. The reporting person exercised stock options for 14,625 shares at $135.42 and for 6,125 and 1,750 shares at $146.03 through family trusts, then sold 14,625 shares and 7,875 shares at $417.4965.
Following these transactions, indirect holdings shown include 130 shares by one trust. Derivative securities beneficially owned following the transactions include 55,875 options (Trust (2)) and 18,375 options (Trust (3)), with specified vesting and expiration dates.
United Therapeutics (UTHR) disclosed an insider update: a director filed a Form 4 noting a transfer of 225 shares of common stock on 09/09/2024 from a jointly held account to an account in which he has no beneficial interest. The entry shows Transaction Code G at a reported price of $0.00.
The filing states the transfer was done without the reporting person’s knowledge and was discovered recently, which caused subsequent Forms 4 to overstate his beneficial holdings. Following the correction, the director reports 4,640 shares held directly.
United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO, who is also a director. Under a pre‑arranged Rule 10b5‑1 plan, the insider exercised 8,000 stock options at $120.26 and sold 8,000 shares over two days.
On 10/23/2025, 4,000 options were exercised and 4,000 shares were sold at weighted average prices including $421.6298, $422.575, and $424.16. On 10/24/2025, another 4,000 options were exercised and 4,000 shares were sold at weighted average prices including $423.558, $424.6351, and $426.4. Following these transactions, direct holdings were 130 shares, with additional indirect holdings reported as 166 shares by spouse and trusts holding 324,518; 258,117; 45,596; and 15,962 shares. Stock options remaining were reported at 154,000.
The 10b5‑1 plan, entered on May 2, 2025, will continue until the earlier of the exhaustion of a 294,000‑option tranche expiring March 15, 2026 or December 31, 2025.
United Therapeutics (UTHR) reported insider activity by its Chairperson & CEO. Under a pre-arranged Rule 10b5-1 plan, the executive exercised 8,000 stock options at $120.26 on 10/21–10/22/2025 and sold 8,000 shares in related transactions at weighted average prices ranging from $420.00 to $432.20. The plan continues until the earlier of exhaustion of a tranche of 294,000 options expiring 03/15/2026 or 12/31/2025.
After these trades, direct holdings were 130 shares. Indirect holdings were disclosed as 166 shares by spouse and trust positions of 324,518; 258,117; 45,596; and 15,962 shares. Remaining stock options beneficially owned were 162,000 with an expiration of 03/15/2026.
United Therapeutics (UTHR) President and COO reported Form 4 transactions on 10/20/2025 under a Rule 10b5-1 plan. The reporting person exercised 14,625 stock options at $135.42 and 7,875 stock options at $146.03, then sold the resulting shares at an average sale price of $427.409, all through trusts described in the filing.
Following these transactions, the filing lists 2,648 shares of common stock as directly owned. Table II shows remaining option holdings of 70,500 options (trust) and 1,750 options (trust) after the reported exercises.
United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO. On 10/17/2025 and 10/20/2025, the reporting person exercised 8,000 stock options at an exercise price of $120.26 and sold 8,000 shares in multiple trades under a pre-arranged Rule 10b5-1 plan entered on May 2, 2025.
Sales on 10/17 occurred at weighted average prices of $430.0517 and $432.3064; sales on 10/20 occurred at weighted average prices of $421.0416, $422.3, $424.6826, $427.555, and $434.22. Following these transactions, direct holdings shown were 130 shares, with additional indirect holdings listed across family trusts and by spouse. The plan continues until the earlier of exhaustion of a 294,000-option tranche expiring March 15, 2026, or December 31, 2025.
United Therapeutics (UTHR) disclosed insider transactions by its Chairperson & CEO under a pre-arranged Rule 10b5-1 plan. On 10/15/2025, the officer exercised 4,000 stock options at $120.26 and sold 4,000 common shares in three trades at weighted average prices of $433.42, $434.8 and $436.4721. On 10/16/2025, the officer exercised 4,000 options at $120.26 and sold 4,000 shares at weighted averages of $430.2253, $431.5085 and $432.86.
Direct common stock holdings were 130 shares after each day’s transactions. Derivative holdings were 182,000 options after 10/15/2025 and 178,000 after 10/16/2025. The 10b5-1 plan, entered on May 2, 2025, continues until a 294,000-option tranche is exhausted or December 31, 2025.
United Therapeutics (UTHR) executive action: The company’s President and COO reported option exercises and same‑day share sales on 10/13/2025 under a Rule 10b5‑1 plan entered into on June 3, 2025.
Two option tranches were exercised: 14,625 options at an exercise price of $135.42 and 7,875 options at $146.03. The resulting shares were sold at $440.3539 per share through trusts referenced in the filing. Following these transactions, direct ownership stood at 2,648 shares, while derivative holdings remained, including options indirectly held through the noted trusts.